62.75 -0.30 (-0.48%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
60.65
Today’s High
64.1
52 Week Low
38.7
52 Week High
69.6
62.90 -0.15 (-0.24%)
- 1D
- 5D
- 1M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
61.4
Today’s High
64.1
52 Week Low
38.6
52 Week High
69.6
Key Metrics
- Market Cap (In Cr) 2857.2
- Beta 1.37
- Div. Yield (%) 0.4
- P/B 2.15
- TTM P/E 9.57
- Peg Ratio 0.47
- Sector P/E 30.46
- D/E 0.08
- Open Price 60.65
- Prev Close 63.05
Analysis
Price Analysis
-
1 Week1.69%
-
3 Months24.36%
-
6 Month26.23%
-
YTD8.24%
-
1 Year13.91%
Risk Meter
- 32% Low risk
- 32% Moderate risk
- 32% Balanced Risk
- 32% High risk
- 32% Extreme risk
Recos
1 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- Strong Sell
- 0
- Sell
- 0
- Hold
- 0
- Buy
- 0
- Strong Buy
- 1
Marksans Pharma News
Markets could be volatile as investors eye GDP data; banks, airlines in focus
3 min read . 31 May 2021Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 1490.84
- Selling/ General/ Admin Expenses Total
- 454.15
- Depreciation/ Amortization
- 44.78
- Other Operating Expenses Total
- 29.8
- Total Operating Expense
- 1276.74
- Operating Income
- 214.1
- Net Income Before Taxes
- 247.51
- Net Income
- 184.57
- Diluted Normalized EPS
- 4.51
- Period
- 2022
- Total Assets
- 1640.1
- Total Liabilities
- 437.83
- Total Equity
- 1202.27
- Tangible Book Valueper Share Common Eq
- 27.21
- Period
- 2022
- Cashfrom Operating Activities
- 99.26
- Cashfrom Investing Activities
- -41.69
- Cashfrom Financing Activities
- 79.51
- Net Changein Cash
- 137.08
- Period
- 2021
- Total Revenue
- 1376.18
- Selling/ General/ Admin Expenses Total
- 402.25
- Depreciation/ Amortization
- 36.15
- Other Operating Expenses Total
- 15.72
- Total Operating Expense
- 1072.72
- Operating Income
- 303.46
- Net Income Before Taxes
- 302.16
- Net Income
- 235.94
- Diluted Normalized EPS
- 5.88
- Period
- 2021
- Total Assets
- 1228.25
- Total Liabilities
- 341.76
- Total Equity
- 886.49
- Tangible Book Valueper Share Common Eq
- 20.02
- Period
- 2021
- Cashfrom Operating Activities
- 178.74
- Cashfrom Investing Activities
- -44.9
- Cashfrom Financing Activities
- -15.29
- Net Changein Cash
- 118.56
- Period
- 2020
- Total Revenue
- 1134.21
- Selling/ General/ Admin Expenses Total
- 317.99
- Depreciation/ Amortization
- 26.66
- Other Operating Expenses Total
- 32.68
- Total Operating Expense
- 968.62
- Operating Income
- 165.59
- Net Income Before Taxes
- 157.17
- Net Income
- 117.02
- Diluted Normalized EPS
- 2.97
- Period
- 2020
- Total Assets
- 902.67
- Total Liabilities
- 266.65
- Total Equity
- 636.01
- Tangible Book Valueper Share Common Eq
- 13.76
- Period
- 2020
- Cashfrom Operating Activities
- 209.94
- Cashfrom Investing Activities
- -59.53
- Cashfrom Financing Activities
- -90.15
- Net Changein Cash
- 60.27
- Period
- 2019
- Total Revenue
- 1000.07
- Selling/ General/ Admin Expenses Total
- 302.96
- Depreciation/ Amortization
- 22.8
- Other Operating Expenses Total
- 28.19
- Total Operating Expense
- 890.73
- Operating Income
- 109.33
- Net Income Before Taxes
- 104.31
- Net Income
- 76.46
- Diluted Normalized EPS
- 1.94
- Period
- 2019
- Total Assets
- 803.71
- Total Liabilities
- 261.23
- Total Equity
- 542.48
- Tangible Book Valueper Share Common Eq
- 11.5
- Period
- 2019
- Cashfrom Operating Activities
- 27.4
- Cashfrom Investing Activities
- -13.48
- Cashfrom Financing Activities
- -20.78
- Net Changein Cash
- -6.86
- Period
- 2018
- Total Revenue
- 912.69
- Selling/ General/ Admin Expenses Total
- 260.42
- Depreciation/ Amortization
- 26.84
- Other Operating Expenses Total
- 17.74
- Total Operating Expense
- 861.09
- Operating Income
- 51.6
- Net Income Before Taxes
- 49.8
- Net Income
- 32.94
- Diluted Normalized EPS
- 1
- Period
- 2018
- Total Assets
- 732.19
- Total Liabilities
- 261.32
- Total Equity
- 470.86
- Tangible Book Valueper Share Common Eq
- 9.23
- Period
- 2018
- Cashfrom Operating Activities
- 50.09
- Cashfrom Investing Activities
- -38.81
- Cashfrom Financing Activities
- 3.38
- Net Changein Cash
- 14.67
- Period
- 2017
- Total Revenue
- 767.16
- Selling/ General/ Admin Expenses Total
- 238.29
- Depreciation/ Amortization
- 30.09
- Other Operating Expenses Total
- 14.01
- Total Operating Expense
- 764.34
- Operating Income
- 2.83
- Net Income Before Taxes
- 14.9
- Net Income
- 8.84
- Diluted Normalized EPS
- 0.22
- Period
- 2017
- Total Assets
- 751.81
- Total Liabilities
- 318.37
- Total Equity
- 433.43
- Tangible Book Valueper Share Common Eq
- 8.09
- Period
- 2017
- Cashfrom Operating Activities
- 8.84
- Cashfrom Investing Activities
- -20.84
- Cashfrom Financing Activities
- 1.86
- Net Changein Cash
- -10.14
- Period
- 2022-09-30
- Total Revenue
- 452.56
- Selling/ General/ Admin Expenses Total
- 59.67
- Depreciation/ Amortization
- 14.05
- Other Operating Expenses Total
- 89.41
- Total Operating Expense
- 386.35
- Operating Income
- 66.22
- Net Income Before Taxes
- 77.83
- Net Income
- 61.25
- Diluted Normalized EPS
- 1.52
- Period
- 2022-09-30
- Total Assets
- 1668.2
- Total Liabilities
- 404.91
- Total Equity
- 1263.29
- Tangible Book Valueper Share Common Eq
- 28.45
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 75.2
- Cashfrom Investing Activities
- 19.51
- Cashfrom Financing Activities
- -56.04
- Net Changein Cash
- 38.75
- Period
- 2022-06-30
- Total Revenue
- 433.77
- Selling/ General/ Admin Expenses Total
- 56.62
- Depreciation/ Amortization
- 11.12
- Other Operating Expenses Total
- 89.47
- Total Operating Expense
- 372.02
- Operating Income
- 61.75
- Net Income Before Taxes
- 76.45
- Net Income
- 59.71
- Diluted Normalized EPS
- 1.46
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 418.04
- Selling/ General/ Admin Expenses Total
- 60.36
- Depreciation/ Amortization
- 21.36
- Other Operating Expenses Total
- 82.43
- Total Operating Expense
- 375.76
- Operating Income
- 42.28
- Net Income Before Taxes
- 52.6
- Net Income
- 28.11
- Diluted Normalized EPS
- 0.69
- Period
- 2022-03-31
- Total Assets
- 1640.1
- Total Liabilities
- 437.83
- Total Equity
- 1202.27
- Tangible Book Valueper Share Common Eq
- 27.21
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 99.26
- Cashfrom Investing Activities
- -41.69
- Cashfrom Financing Activities
- 79.51
- Net Changein Cash
- 137.08
- Period
- 2021-12-31
- Total Revenue
- 362.63
- Selling/ General/ Admin Expenses Total
- 56.1
- Depreciation/ Amortization
- 8.56
- Other Operating Expenses Total
- 81.2
- Total Operating Expense
- 313.39
- Operating Income
- 49.24
- Net Income Before Taxes
- 60.35
- Net Income
- 49.12
- Diluted Normalized EPS
- 1.2
- Period
- 2021-12-31
- Period
- 2021-12-31
- Period
- 2021-09-30
- Total Revenue
- 710.16
- Selling/ General/ Admin Expenses Total
- 103.84
- Depreciation/ Amortization
- 14.86
- Other Operating Expenses Total
- 131.21
- Total Operating Expense
- 587.58
- Operating Income
- 122.58
- Net Income Before Taxes
- 134.56
- Net Income
- 107.34
- Diluted Normalized EPS
- 2.62
- Period
- 2021-09-30
- Total Assets
- 1407.04
- Total Liabilities
- 311.24
- Total Equity
- 1095.8
- Tangible Book Valueper Share Common Eq
- 25.19
- Period
- 2021-09-30
- Cashfrom Operating Activities
- 45.85
- Cashfrom Investing Activities
- -92.32
- Cashfrom Financing Activities
- 86.78
- Net Changein Cash
- 40.31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day62.87
- 10 Day63.48
- 20 Day64.66
- 50 Day62.02
- 100 Day56.18
- 300 Day52.54
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Advanced Enzyme Technologies
- 276.55
- -3.7
- -1.32
- 336.45
- 257
- 3132.14
- Indoco Remedies
- 332
- -3.55
- -1.06
- 425.12
- 307.95
- 3092.11
- Marksans Pharma
- 62.75
- -0.3
- -0.48
- 69.6
- 38.7
- 2897.98
- Wockhardt
- 194.7
- -0.6
- -0.31
- 386.99
- 191.05
- 2783.96
- Strides Pharma Science
- 299.55
- 0.3
- 0.1
- 404
- 263.45
- 2727.75
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Advanced Enzyme Technologies
- 26.39
- 2.85
- 15.57
- 26.97
- Indoco Remedies
- 19.79
- 3.42
- 8.71
- 5.26
- Marksans Pharma
- 14.18
- 2.18
- 19.29
- 11.2
- Wockhardt
- -
- 0.72
- -10.45
- -10.27
- Strides Pharma Science
- -
- 1.15
- -0.14
- -0.17
Shareholding
- Category
- Percentage
- No. of shares
- Public Shareholding
- 56.2%
- 254,672,013
- Others
- 30.14%
- 136,585,157
- OrbiMed Asia IV Mauritius FVCI Limited
- 10.88%
- 49,324,324
- Others
- 5.05%
- 22,895,525
- Others
- 3.71%
- 16,817,930
- Others
- 2.05%
- 9,288,224
- Others
- 1.65%
- 7,492,808
- HUF
- 1.29%
- 5,847,677
- Clearing Members
- 0.16%
- 711,807
- Employees Relatives
- 0.01%
- 26,328
- Employees
- 0%
- 15,687
- Trusts
- 0%
- 3,000
- Others
- 0.86%
- 3,875,804
- Others
- 0.23%
- 1,058,219
- Others
- 0.14%
- 650,852
- Others
- 0.02%
- 75,760
- Others
- 0%
- 2,911
- Promoter & Promoter Group Shareholding
- 43.8%
- 198,491,733
- MARK SALDANHA
- 43.8%
- 198,491,553
- SANDRA SALDANHA
- 0%
- 180
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 13-Feb-23
- Quarterly Results
- 20-Jan-23
- Others
- 14-Nov-22
- Quarterly Results
- 13-Aug-22
- Quarterly Results
- 08-Jul-22
- Buy Back of shares
- 30-May-22
- Audited Results & Final Dividend
- 11-Feb-22
- Quarterly Results
- 10-Nov-21
- Quarterly Results
- 09-Nov-21
- Quarterly Results
- 11-Aug-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 23-Sept-21
- 11-Aug-21
- AGM
- 09-Jul-21
- 16-Jun-21
- EGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 30-May-22
- -
- -
- 0.25
- 31-May-21
- -
- 15-Sept-21
- 0.25
No recent bonus announcements.
No recent splits available.
No recent rights issue declared.
Company Profile
ABOUT Marksans Pharma
- Industry Biotechnology & Drugs
- ISIN INE750C01026
- BSE Code 524404
- NSE Code MARKSANS
Marksans Pharma Limited is an India-based pharmaceutical company. The Company operates through the manufacture of pharmaceutical formulation segment. The Company is primarily engaged in the research, manufacturing and marketing of generic pharmaceutical formulations with three state-of-the-art facilities in India, the United Kingdom and the United States. It marks its presence across different therapeutic areas in the region, such as pain management, diabetes, cough and cold, neurology, cardiovascular and hormonal treatment. The Company has a manufacturing facility for the manufacture of oral solid tablets, soft gelatin capsules and hard capsules in Goa. It also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The Company has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.
MANAGEMENT
- Mark Saldanha Executive Chairman of the Board, Managing Director
- Jitendra Sharma Chief Financial Officer
- Harshavardhan Panigrahi Compliance Officer, Company Secretary and Legal Manager
- Varddhman Jain Whole Time Director
- Sandra Saldanha Whole Time Director
Company Summary
MARKSANS PHARMA SUMMARY
Marksans Pharma is trading 0.48% lower at Rs 62.75 as compared to its last closing price. Marksans Pharma has been trading in the price range of 64.1 & 60.65. Marksans Pharma has given 8.24% in this year & 1.69% in the last 5 days.
Marksans Pharma has TTM P/E ratio 9.57 as compared to the sector P/E of 30.46. There are 1 analysts who have initiated coverage on Marksans Pharma. There are 1 analysts who have given it a strong buy rating & 0 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.
The company posted a net profit of 61.25 Crores in its last quarter.
Listed peers of Marksans Pharma include Advanced Enzyme Technologies (-1.32%), Indoco Remedies (-1.06%), Marksans Pharma (-0.48%) etc.
Marksans Pharma has a 43.8% promoter holding & 56.2% public holding.
FAQs about Marksans Pharma
Marksans Pharma is trading at 62.75 as on 9 Feb, 2023 3:29:30 PM. This is -0.48% lower as compared to its previous closing price of 63.05
The market capitalization of Marksans Pharma is 2857.2 Cr as on 9 Feb, 2023 3:29:30 PM.
The average broker rating on Marksans Pharma is Strong Buy. The breakup of analyst rating is given below -
- 0 analysts have given a strong sell rating
- 0 analysts have given a sell rating
- 0 analysts have given a hold rating
- 0 analysts have given a buy rating
- 1 analysts have given a strong buy rating
The 52 wk high for Marksans Pharma is 69.6 whereas the 52 wk low is 38.7
Marksans Pharma can be analyzed on the following key metrics -
- TTM P/E: 9.57
- Sector P/E: 30.46
- Dividend Yield: 0.4%
- D/E ratio: -
Marksans Pharma reported a net profit of 184.57 Cr in 2022.
